News Issued: May 30, 2024 (9:45am EDT) To view this online and get more information about Novavax Investor Relations visit: NOVAVAX TO PARTICIPATE IN 2024 JEFFERIES GLOBAL HEALTHCARE CONFERENCE GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 6, 2024 Time: 12:30 – 12:55 p.m. Eastern Time (ET) Location: New York, NY Moderator: Roger Song, MD, CFA, Equity Research Analyst – Biotechnology Novavax participant: John C. Jacobs, President and Chief Executive Officer Conference Event: Investor Meetings Date: Thursday, June 6, 2024 Recordings A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference. About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts: Investors Erika Schultz 240-268-2022 [email protected] Media Giovanna Chandler 240-720-7804 [email protected] SOURCE Novavax, Inc.